Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study-Reference-Cited by-同舟云学术

Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study

Published:2017-04-21 Issue:4 Volume:12 Page:e0176276
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Trotta Francesco,Spila-Alegiani Stefania,Da Cas Roberto,Rajevic Maja,Conti Valentino,Venegoni Mauro,Rossi Mariangela,Traversa Giuseppe

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference23 articles.

1. Global Strategy for Diagnosis, Management, and Prevention of COPD from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (date last accessed June 1 2016).

2. The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2014. Rome: Italian Medicines Agency, 2015. http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2014_0.pdf (date last accessed June 1 2016).

3. Spiriva^® Summary of Product Characteristics. Banca dati farmaci. Agenzia Italiana del Farmaco. https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/ (accessed 1 June 2016).

4. Spiriva^® Respimat^® Summary of Product Characteristics. Banca dati farmaci. Agenzia Italiana del Farmaco. https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/ (date last accessed June 1 2016).

5. Call for worldwide withdrawal of tiotropium Respimat mist inhaler;R Beasley;BMJ,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences;Therapeutic Advances in Chronic Disease;2023-01

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers

;International Journal of Chronic Obstructive Pulmonary Disease;2020-12

3. M3, a 1,4-Dihydropyridine Derivative and Mixed L-/T-Type Calcium Channel Blocker, Attenuates Isoproterenol-Induced Toxicity in Male Wistar Rats;Cardiovascular Toxicology;2020-07-15

4. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists;Cardiovascular Complications of Respiratory Disorders;2020-06

5. Inhalative Therapie bei COPD und Asthma;Therapeutische Umschau;2019-11